/Investor DB

Wu Capital — Full Portfolio

8 tracked investments · listed companies and verified rows first

Korro Biokorrobio.comin𝕏NASDAQ: KRROSep 2020 · $91.5M

Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology.

BiotechHealthtechCambridge, US

Nessan Bermingham(Mr. Bermingham is the Executive Chair of the Issuer.)inJean-François Formela(Director)inOmmer Chohan(Mr. Chohan is the Secretary and Treasurer of the Issuer.)inRam Aiyar(Chief Executive Officer, President and Director)inTodd Chappell(Chief Operating Officer)in

Co-investorsAtlas VentureMC Healthcare VenturesNew Enterprise Associates (NEA)AlexandriaQiming Venture PartnersQiming Venture Partners USA+3 more

Laiyelaiye.comin✓ verified

Laiye offers a Work Execution Platform that lets government and enterprise clients build LLM-driven digital workforces, combining RPA, conversational AI, and intelligent document processing to automate business processes.

AI & Machine LearningEnterprise SoftwareSaaSBeijing, CN

Yichuan Hu(Founder)in

Co-investorsCathay InnovationDCP CapitalLightspeed Venture PartnersSequoia CapitalZhenFundActivant Capital+2 more

Ariesaries.comMay 2018 · $128M

Aries offers a trading platform where users can trade individual stocks, ETFs, options, and index options in a single application.

Data & InfrastructureDeveloper ToolsFintechSaaS

RedaPash

Co-investorsID VenturesMichigan RiseShenzhen Capital GroupVision Plus CapitalYunqi Partners

Cobocobo.comin𝕏

Cobo is a digital asset infrastructure company that provides custody and wallet technology, including Wallet-as-a-Service, to help organizations and developers manage and secure cryptocurrency and digital assets.

Crypto & Web3Data & InfrastructureEnterprise SoftwareFintechHong Kong, HK

Changhao Jiang(CTO and Co-founder)inLily Z. KinginMao Shixing(CEO and Co-founder)

Co-investorsDST GlobalIMO VenturesBitDAOBN CapitalCyberport Hong KongLinear Capital+3 more

Inipharminipharm.comin

Inipharm is a clinical-stage biopharmaceutical company developing small-molecule inhibitors targeting HSD17B13 to treat severe fibrotic liver diseases, including MASH and other conditions with established genetic validation.

BiotechHealthtechMedical Devices

Brian Farmer(Co-Founder, Chief Executive Officer)inHeather Hsu, PhD(Co-Founder, Chief Scientific Officer)Michael Gallatin, PhD(Co-Founder, SAB Chair)Chuhan Chung(Chief Medical Officer)in

Co-investors5AM VenturesFrazier Life SciencesFrazier Healthcare Partners

Pingletsping.comin𝕏Apr 2021 · $50M

Ping is a fintech platform offering free USD accounts and global payment solutions for freelancers and international workers.

Crypto & Web3FintechBuenos Aires, AR

Mary Saracco(Founder)inPablo Orlando(Founder)inJack Saracco(Founder)inNico BayerquePablo Orlandoin

Co-investorsY CombinatorGeneral CatalystGoat CapitalLightspeed Venture PartnersLuminous VenturesRibbit Capital+1 more

Sanjiekesanjieke.cnMay 2019

Sanjieke is a China-based digital talent training provider that offers online learning platforms and courses to enterprises and individuals for digital transformation and workforce upskilling.

AI & Machine LearningEdTechEnterprise SoftwareSaaSBeijing, CN

后显慧 (Luke Hou)(Founder & CEO)徐财星(Founder)in

Co-investorsOwl VenturesIDG CapitalUdemy

Semma Therapeuticssemma-tx.comNov 2017acquired by Vertex Pharmaceuticals · Sep 2019 · $950M

Cambridge, MA biotech developing stem cell-derived islet therapy plus an immune-protective device for type 1 diabetes; acquired by Vertex for $950M.

BiotechCambridge, US

Robert Millman(Executive Officer, Director)

BoardTodd Foley(Executive Officer, Director)inMitch Finer(Director)Stephen Knight(Director)inJim Scopa(Director)William Sahlman(Director)

Co-investorsARCH Venture PartnersF-Prime CapitalJDRF T1D FundORI CapitalSlater Technology Fund6 Dimensions Capital+4 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.